MX2017002277A - Anticuerpos que potencian el factor h y sus usos. - Google Patents

Anticuerpos que potencian el factor h y sus usos.

Info

Publication number
MX2017002277A
MX2017002277A MX2017002277A MX2017002277A MX2017002277A MX 2017002277 A MX2017002277 A MX 2017002277A MX 2017002277 A MX2017002277 A MX 2017002277A MX 2017002277 A MX2017002277 A MX 2017002277A MX 2017002277 A MX2017002277 A MX 2017002277A
Authority
MX
Mexico
Prior art keywords
factor
antibodies
potentiating antibodies
fragments
potentiating
Prior art date
Application number
MX2017002277A
Other languages
English (en)
Inventor
Willem Kuijpers Taco
Wouters Diana
Clara Brouwer Maria
Benjamin Pouw Richard
Original Assignee
Stichting Sanquin Bloedvoorziening
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stichting Sanquin Bloedvoorziening filed Critical Stichting Sanquin Bloedvoorziening
Publication of MX2017002277A publication Critical patent/MX2017002277A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La invención se refiere a anticuerpos aislados, sintéticos o recombinantes y fragmentos de ellos específicos para el factor H. La invención se refiere además al uso de dichos anticuerpos y fragmentos para inhibir la activación del complemento y para el tratamiento de trastornos asociados con la activación del complemento.
MX2017002277A 2014-08-20 2015-08-20 Anticuerpos que potencian el factor h y sus usos. MX2017002277A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14181631 2014-08-20
PCT/NL2015/050584 WO2016028150A1 (en) 2014-08-20 2015-08-20 Factor h potentiating antibodies and uses thereof

Publications (1)

Publication Number Publication Date
MX2017002277A true MX2017002277A (es) 2017-08-10

Family

ID=51357866

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017002277A MX2017002277A (es) 2014-08-20 2015-08-20 Anticuerpos que potencian el factor h y sus usos.

Country Status (12)

Country Link
US (2) US10112993B2 (es)
EP (1) EP3183266B1 (es)
JP (2) JP6965157B2 (es)
KR (1) KR20170058922A (es)
CN (1) CN107074939B (es)
AU (1) AU2015304079B2 (es)
BR (2) BR122023020102A2 (es)
CA (1) CA2958537C (es)
ES (1) ES2739609T3 (es)
IL (1) IL250667B2 (es)
MX (1) MX2017002277A (es)
WO (1) WO2016028150A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020007555A (es) 2018-01-15 2021-01-15 Stichting Sanquin Bloedvoorziening Anticuerpos potenciadores del factor h y usos de los mismos.
GB201800620D0 (en) 2018-01-15 2018-02-28 Univ Manchester C3b Binding Polypeptide
CN114828886A (zh) * 2019-07-17 2022-07-29 双子治疗分公司 因子h增强抗体及其用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090004183A1 (en) * 2004-07-23 2009-01-01 Taylor Ronald P Compositions and Methods for Regulating the Alternative Pathway of Complement
WO2007056227A2 (en) * 2005-11-04 2007-05-18 Genentech, Inc. Use of complement pathway inhibitors to treat ocular diseases
FR2894145B1 (fr) 2005-12-07 2008-10-17 Lab Francais Du Fractionnement Utilisation de facteur h du complement a titre de medicament
KR101572700B1 (ko) * 2007-06-07 2015-11-30 제넨테크, 인크. 보체-관련 장애의 예방 및 치료를 위한 Ｃ３ｂ 항체 및 방법
GB0819633D0 (en) * 2008-10-25 2008-12-03 Isis Innovation Composition
CN107661491A (zh) * 2010-09-15 2018-02-06 赛尔戴克斯治疗公司 用可溶性I型补体受体(sCR1)治疗慢性肾病
AU2013326932B2 (en) * 2012-10-04 2019-06-06 Novelmed Therapeutics, Inc. Alternative pathway specific antibodies for treating hemolytic diseases
TW201605904A (zh) * 2013-11-07 2016-02-16 諾佛 儂迪克股份有限公司 治療凝血病變之新穎方法及抗體
US10357554B2 (en) * 2013-11-11 2019-07-23 The United States Of America, As Represented By The Secretary Of The Army AMA-1 epitopes, antibodies, compositions, and methods of making and using the same

Also Published As

Publication number Publication date
IL250667B2 (en) 2023-10-01
IL250667A0 (en) 2017-04-30
BR122023020102A2 (pt) 2023-12-12
CA2958537C (en) 2023-04-25
US10112993B2 (en) 2018-10-30
AU2015304079B2 (en) 2021-05-13
BR112017003200A2 (pt) 2017-11-28
KR20170058922A (ko) 2017-05-29
US20170355753A1 (en) 2017-12-14
ES2739609T3 (es) 2020-02-03
IL250667B1 (en) 2023-06-01
US20190194304A1 (en) 2019-06-27
EP3183266B1 (en) 2019-05-29
EP3183266A1 (en) 2017-06-28
CA2958537A1 (en) 2016-02-25
BR112017003200B1 (pt) 2023-12-26
AU2015304079A1 (en) 2017-04-06
CN107074939B (zh) 2021-09-07
CN107074939A (zh) 2017-08-18
WO2016028150A1 (en) 2016-02-25
JP2017525362A (ja) 2017-09-07
JP2021178857A (ja) 2021-11-18
JP6965157B2 (ja) 2021-11-10

Similar Documents

Publication Publication Date Title
MX2020009649A (es) Anticuerpos monoclonales contra bcma.
PH12017502180A1 (en) Tau-binding antibodies
MY193723A (en) Combination therapy of tumor-targeted il-2 variant immunocytokines and antibodies against human pd-l1
MX2019003623A (es) Composiciones y metodos para el tratamiento de afecciones oftalmicas.
MX2020002694A (es) Moleculas de anticuerpo que se unen a tim-3 y usos de las mismas.
MD20170035A2 (ro) Compoziţii şi metode de utilizare pentru tratamentul tulburărilor metabolice
PH12017500002A1 (en) Anti-cdh6 antibody drug conjugates
PH12017502207A1 (en) Tau-binding antibodies
PH12017500621A1 (en) Triazolopyrazinones as pde1 inhibitors
NZ725568A (en) Modified j-chain
MX2016012371A (es) Anticuerpos multiespecificos.
MX2018010295A (es) Anticuerpos que tienen especificidad para atenuador de linfocitos b y t (btla) y usos de los mismos.
EP4272738A3 (en) Anti-cd38 antibodies for treatment of acute lymphoblastic leukemia
MY176855A (en) Anti-jagged1 antibodies and methods of use
PH12019502002A1 (en) Combination theraphy
MX2017003211A (es) Anticuerpos anti-met y composiciones.
MX2016009590A (es) Composiciones de apilimod y métodos para usar las mismas.
MX2020007555A (es) Anticuerpos potenciadores del factor h y usos de los mismos.
MX2020003219A (es) Anticuerpos que tienen especificidad para btn2 y usos de los mismos.
MX2016016233A (es) Anticuerpos anti-lgr5 y sus usos.
MX2017002277A (es) Anticuerpos que potencian el factor h y sus usos.
PH12016501495A1 (en) Hexahydrofuropyrroles as pde1 inhibitors
MX2017006692A (es) Trastornos neurodegenerativos.
MA40642A (fr) Nouveaux dérivés peptidiques et leurs utilisations